Maria Giuseppa Vitale
Overview
Explore the profile of Maria Giuseppa Vitale including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piombino C, Nasso C, Bettelli S, Manfredini S, Vitale M, Pipitone S, et al.
Cancer Med
. 2025 Feb;
14(4):e70472.
PMID: 39980141
Background: The therapeutic management of metastatic hormone-sensitive prostate cancer (mHSPC) is still based on clinical and pathological parameters due to the lack of biomarkers that may drive tailored treatment. Methods:...
2.
Extravasation of enfortumab vedotin: a case report and literature review on antibody-drug conjugates
Pipitone S, Vitale M, Baldessari C, Sabbatini R, Dominici M, Porretta Serapiglia C, et al.
Eur J Hosp Pharm
. 2025 Feb;
PMID: 39904594
Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) indicated for advanced or metastatic urothelial carcinoma. We describe a case of EV extravasation in a patient with metastatic bladder cancer. The...
3.
Tonni E, Oltrecolli M, Pirola M, Tchawa C, Roccabruna S, DAgostino E, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273642
The standard of care for advanced or metastatic urothelial carcinoma (mUC) was historically identified with platinum-based chemotherapy. Thanks to the advances in biological and genetic knowledge and technologies, new therapeutic...
4.
Ciccarese C, Buttner T, Cerbone L, Zampiva I, Monteiro F, Basso U, et al.
Int J Cancer
. 2024 Sep;
155(11):2036-2046.
PMID: 39243397
Metastatic renal cell carcinoma (mRCC) carrying sarcomatoid features (sRCC) has aggressive biology and poor prognosis. First-line immunotherapy (IO)-based combinations have improved the outcome of clear cell RCC patients, including that...
5.
Rizzo M, Soares A, Grande E, Bamias A, Manneh Kopp R, Lenci E, et al.
Sci Rep
. 2024 Aug;
14(1):19802.
PMID: 39187558
The addition of metastasis-directed radiotherapy (MDRT) to immunotherapy in patients with advanced urothelial carcinoma (aUC) has shown promising results. We report the real-world data from the ARON-2 study (NCT05290038) on...
6.
Piombino C, Pipitone S, Tonni E, Mastrodomenico L, Oltrecolli M, Tchawa C, et al.
Int J Mol Sci
. 2024 May;
25(9).
PMID: 38731844
More than 20% of metastatic prostate cancer carries genomic defects involving DNA damage repair pathways, mainly in homologous recombination repair-related genes. The recent approval of olaparib has paved the way...
7.
Fiala O, Buti S, Bamias A, Massari F, Pichler R, Maruzzo M, et al.
Target Oncol
. 2024 May;
19(4):587-599.
PMID: 38704759
Background: About 20% of patients with renal cell carcinoma present with non-clear cell histology (nccRCC), encompassing various histological types. While surgery remains pivotal for localized-stage nccRCC, the role of cytoreductive...
8.
Vitale M, Nasso C, Ricco B, Bocconi A, Chiavelli C, Baldessari C, et al.
Case Rep Oncol
. 2024 Apr;
17(1):564-572.
PMID: 38645572
Introduction: Vaginal cancer is a rare gynecologic malignancy. While in a localized disease, concurrent chemoradiation grants local control and better overall survival, in a metastatic setting, the management options are...
9.
Buti S, Olivari A, Masini C, Bimbatti D, Sartori D, Ermacora P, et al.
Ther Adv Urol
. 2024 Apr;
16:17562872241244574.
PMID: 38638242
Background: The treatment of heavily pretreated patients with metastatic renal cell carcinoma (mRCC) represents an unmet medical need and is still challenging. Objectives: The primary objective was to assess the...
10.
Mollica V, Massari F, Maruzzo M, Bimbatti D, Claps M, Maiorano B, et al.
Clin Genitourin Cancer
. 2024 Apr;
22(3):102074.
PMID: 38616147
Introduction: Penile squamous cell carcinoma (PSCC) is a rare tumor with an aggressive behavior. The Meet-URO 23/I-RARE registry includes rare genitourinary malignancies. We extracted patients with PSCC to conduct a...